Cidara Therapeutics (NASDAQ:CDTX) Downgraded to "Buy" at StockNews.com
Cidara Therapeutics (NASDAQ:CDTX) Downgraded to "Buy" at StockNews.com
StockNews.com downgraded shares of Cidara Therapeutics (NASDAQ:CDTX – Get Rating) from a strong-buy rating to a buy rating in a research note issued to investors on Monday.
StockNews.com 下调了股票评 Cidara Therapeutics（纳斯达克股票代码：CDTX — 获取评级） 从周一发布给投资者的研究报告中的强势买入评级到买入评级。
Cidara Therapeutics Stock Performance
Cidara Therapeutics
CDTX opened at $0.93 on Monday. The firm's 50-day simple moving average is $0.74 and its 200-day simple moving average is $0.69. The firm has a market cap of $66.47 million, a price-to-earnings ratio of -1.69 and a beta of 1.31. Cidara Therapeutics has a twelve month low of $0.40 and a twelve month high of $1.60.
CDTX周一开盘价为0.93美元。该公司的50天简单移动平均线为0.74美元，其200天简单移动平均线为0.69美元。该公司的市值为6647万美元，市盈率为-1.69，beta值为1.31。Cidara Therapeutics创下十二个月低点0.40美元，十二个月高点为1.60美元。
Cidara Therapeutics (NASDAQ:CDTX – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.30 by ($0.13). Cidara Therapeutics had a negative net margin of 54.21% and a negative return on equity of 480.89%. The firm had revenue of $40.74 million during the quarter, compared to analyst estimates of $37.50 million. As a group, sell-side analysts anticipate that Cidara Therapeutics will post -0.29 EPS for the current fiscal year.
Cidara Therapeutics（纳斯达克股票代码：CDTX — 获取评级）上次公布季度财报是在11月3日星期四。这家生物技术公司公布了本季度每股收益0.17美元，比分析师普遍预期的0.30美元（0.13美元）高出0.30美元。Cidara Therapeutics的净利润率为负54.21％，负股本回报率为480.89％。该公司在本季度的收入为4,074万美元，而分析师的估计为3,750万美元。作为一个整体，卖方分析师预计，Cidara Therapeutics将在本财年公布每股收益为-0.29美元。
Institutional Trading of Cidara Therapeutics
Cidara Therapeutic的机构交易
Cidara Therapeutics Company Profile
Cidara Therapeutics
(Get Rating)
（获取评分）
Cidara Therapeutics, Inc is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Cidara Therapeutics, Inc是一家生物技术公司，从事新型抗感染药物的发现、开发和商业化。其产品线包括Rezafungin和Cloudbreak。该公司由 Kevin M. Forrest、Kevin J. Judice 和 H. Shaw Warren 于 2012 年 12 月创立，总部位于加利福尼亚州圣地亚哥。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Cidara Therapeutics (CDTX)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
- 免费获取 StockNews.com 关于 Cidara Therapeutics (CDTX) 的研究报告的副本
- 诺斯罗普·格鲁曼公司的抛售是机会吗？
- 新首席执行官上任 Under Armor 股票的最差表现是否落后？
- 微软对ChatGBT的投资对MSFT股票意味着什么？
- 像 The Fit of Skechers USA
- 我们能相信标准普尔500指数的涨势吗
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Cidara Therapeutics 每日的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Cidara Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。